By Adam Feuerstein
April 30, 2026
Senior Writer, Biotech
Adam Feuerstein
adam.feuerstein@statnews.com
What does Akeso's primo plenary spot say about its survival data?
Mystery cloaks an ASCO plenary lung cancer survival result.
330 words~2 min read
Related reading
Astellas treatment offers new hope to a devastated rare disease community
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
FDA to reconsider treatment for rare cancer after its surprise rejection
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM…
LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case…
Are analysts too quick to gloss over Lilly's liver case?
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Candel reports prostate cancer drug's long-term data ahead of FDA filing
Candel Therapeutics' CEO says long-term data bode well for its prostate cancer drug aglatimagene ahead of an FDA submission.
BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of…
LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the…